Vanda Pharmaceuticals (VNDA) Operating Income Growth (3y) (2013 - 2026)
Vanda Pharmaceuticals (VNDA) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 38.78% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 69.02% |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 55.96% |
| 10 | Vanda Pharmaceuticals | 314.54 Mn | 112.23 Mn | 48.56 Mn | -200.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -200.23% |
| Dec 31, 2025 | -100.73% |
| Sep 30, 2025 | -115.48% |
| Jun 30, 2025 | -135.88% |
| Mar 31, 2025 | -74.90% |
| Dec 31, 2024 | -47.21% |
| Sep 30, 2024 | -44.49% |
| Jun 30, 2024 | -41.29% |
| Mar 31, 2024 | -42.49% |
| Dec 31, 2023 | -38.88% |
| Sep 30, 2023 | -40.51% |
| Jun 30, 2023 | -32.24% |
| Mar 31, 2023 | 162.23% |
| Dec 31, 2022 | 16.04% |
| Sep 30, 2022 | -28.65% |
| Jun 30, 2022 | -29.54% |
| Mar 31, 2022 | -54.31% |
| Dec 31, 2021 | -1.91% |
| Sep 30, 2021 | 20.18% |
| Jun 30, 2021 | 46.76% |